<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName journalpublishing.dtd?>
<?SourceDTD.Version 2.3?>
<?ConverterInfo.XSLTName jp2nlmx2.xsl?>
<?ConverterInfo.Version 2?>
<front>
  <?epub March-7-2014?>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="hwp">nar</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">4027195</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gku182</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Methods Online</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Inferring probabilistic miRNA–mRNA interaction signatures in cancers: a role-switch approach</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Yue</given-names>
        </name>
        <xref ref-type="aff" rid="AFF1">
          <sup>1</sup>
        </xref>
        <xref ref-type="aff" rid="AFF2">
          <sup>2</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Liang</surname>
          <given-names>Cheng</given-names>
        </name>
        <xref ref-type="aff" rid="AFF2">
          <sup>2</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wong</surname>
          <given-names>Ka-Chun</given-names>
        </name>
        <xref ref-type="aff" rid="AFF1">
          <sup>1</sup>
        </xref>
        <xref ref-type="aff" rid="AFF2">
          <sup>2</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Jin</surname>
          <given-names>Ke</given-names>
        </name>
        <xref ref-type="aff" rid="AFF2">
          <sup>2</sup>
        </xref>
        <xref ref-type="aff" rid="AFF3">
          <sup>3</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Zhaolei</given-names>
        </name>
        <xref ref-type="aff" rid="AFF1">
          <sup>1</sup>
        </xref>
        <xref ref-type="aff" rid="AFF2">
          <sup>2</sup>
        </xref>
        <xref ref-type="aff" rid="AFF3">
          <sup>3</sup>
        </xref>
        <xref ref-type="aff" rid="AFF4">
          <sup>4</sup>
        </xref>
        <xref ref-type="corresp" rid="COR1">*</xref>
      </contrib>
      <aff id="AFF1"><label>1</label>Department of Computer Science, University of Toronto, Toronto, Ontario M5S 3G4, Canada</aff>
      <aff id="AFF2"><label>2</label>The Donnelly Centre, University of Toronto, Toronto, ON M5S 3E1, Canada</aff>
      <aff id="AFF3"><label>3</label>Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A4, Canada</aff>
      <aff id="AFF4"><label>4</label>Banting and Best Department of Medical Research, University of Toronto, Toronto, ON M5S 3E1, Canada</aff>
    </contrib-group>
    <author-notes>
      <corresp id="COR1"><label>*</label>To whom correspondence should be addressed. Tel: +1 416 946 0924; Fax: +1 416 978 8287; Email: <email>zhaolei.zhang@utoronto.ca</email></corresp>
    </author-notes>
    <pub-date pub-type="ppub">
      <day>01</day>
      <month>5</month>
      <year>2014</year>
    </pub-date>
    <pub-date pub-type="epub">
      <day>07</day>
      <month>3</month>
      <year>2014</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>07</day>
      <month>3</month>
      <year>2014</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. -->
    <volume>42</volume>
    <issue>9</issue>
    <fpage>e76</fpage>
    <lpage>e76</lpage>
    <history>
      <date date-type="accepted">
        <day>14</day>
        <month>2</month>
        <year>2014</year>
      </date>
      <date date-type="rev-recd">
        <day>22</day>
        <month>1</month>
        <year>2014</year>
      </date>
      <date date-type="received">
        <day>20</day>
        <month>12</month>
        <year>2013</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2014. Published by Oxford University Press [on behalf of Nucleic Acids Research].</copyright-statement>
      <copyright-year>2014</copyright-year>
      <license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by/3.0/">
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:title="pdf" xlink:type="simple" xlink:href="gku182.pdf"/>
    <abstract>
      <p>Aberrant microRNA (miRNA) expression is implicated in tumorigenesis. The underlying mechanisms are unclear because the regulations of each miRNA on potentially hundreds of mRNAs are sample specific. We describe a novel approach to infer <italic>Pro</italic>babilistic <italic>Mi</italic>RNA–mRNA <italic>I</italic>nteraction <italic>S</italic>ignatur<italic>e</italic> (‘ProMISe’) from a single pair of miRNA–mRNA expression profile. Our model considers mRNA and miRNA competition as a probabilistic function of the expressed seeds (matches). To demonstrate ProMISe, we extensively exploited The Cancer Genome Atlas data. As a target predictor, ProMISe identifies more confidence/validated targets than other methods. Importantly, ProMISe confers higher cancer diagnostic power than using expression profiles alone. Gene set enrichment analysis on averaged ProMISe uniquely revealed respective target enrichments of oncomirs miR-21 and 145 in glioblastoma and ovarian cancers. Moreover, comparing matched breast (BRCA) and thyroid (THCA) tumor/normal samples uncovered thousands of tumor-related interactions. For example, ProMISe–BRCA network involves miR-155/183/21, which exhibits higher ProMISe coupled with coherently higher miRNA expression and lower target expression; oncomirs miR-221/222 in the ProMISe–THCA network engage with many downregulated target genes. Together, our probabilistic approach of integrating expression and sequence scores establishes a functional link between the aberrant miRNA and mRNA expression, which was previously under-appreciated due to the methodological differences.</p>
    </abstract>
    <counts>
      <page-count count="11"/>
    </counts>
    <custom-meta-group>
      <custom-meta>
        <meta-name>cover-date</meta-name>
        <meta-value>2014</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>INTRODUCTION</title>
    <p>MicroRNAs (miRNAs) are small (∼22 nucleotides) RNA molecules that base-pair with mRNA primarily at the 3′ untranslated region (UTR) to cause mRNA degradation or translational repression (<xref rid="B1" ref-type="bibr">1</xref>). Recent studies have linked alterations in miRNA expression with various cancers (<xref rid="B2" ref-type="bibr">2–3</xref>). Functional characterization of miRNAs depends on precise identification of their targets. Earlier developed miRNA target prediction programs are mostly based on sequence complementarity, evolutionary conservation, free energy and/or target site accessibility (<xref rid="B4" ref-type="bibr">4</xref>). Although useful, these sequence-based methods often suffer from high false positive rate and are unable to capture sample-specific interactions. More recently developed methods have incorporated mRNA and miRNA expression data generated by microarrays or RNA-seq to predict functional miRNA–mRNA interactions (MMIs). Despite diverse modeling approaches, a majority of the expression-based methods rely on negative expression correlation between miRNA and mRNA. In terms of model complexity, these methods range from the simplest Pearson correlation to more sophisticated Bayesian method. In particular, GenMiR++ is based on variational Bayesian to infer the posterior probabilities of MMIs as represented by the linear coefficients in a regression framework (<xref rid="B5" ref-type="bibr">5</xref>). Regularized least-squares linear regression such as LASSO has also been used to calculate a sparse linear solution of the most significant MMI (<xref rid="B6" ref-type="bibr">6</xref>).</p>
    <p>While a step forward from the sequence-based methods, there are two important limitations in the current expression-based methods. First, these methods usually require a large number of samples to compute MMIs. Thus, they have difficulty in identifying ‘personalized’ MMIs in individual samples. Indeed, each tissue or cell line has a unique miRNA regulatory network with weighted MMI edges, which can be used as molecular signatures similar to the uniqueness of mRNA/miRNA expression profile (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B7" ref-type="bibr">7</xref>). Second, while most methods take into account the potential competition among miRNAs for the same mRNA in regression models, the reciprocal competition among mRNAs for the same miRNA has not been systematically addressed. Yet both competitions are experimentally supported. For the former, not only the endogenous miRNAs may compete for the same mRNA harboring overlapping seed matches but also for the limited Argonaute (Ago), the catalytic component of the RNA silencing complex (RISC) (<xref rid="B8" ref-type="bibr">8</xref>). For the latter competition, Arvey <italic>et al.</italic> (<xref rid="B9" ref-type="bibr">9</xref>) showed that miRNAs that have a higher number of available target transcripts will downregulate each individual target gene to a lesser extent than those with a lower number of targets. In other words, the affected mRNA target population ‘dilutes’ the individual miRNA effect by sharing target sites among them.</p>
    <p>In this paper, we describe three related models via a novel approach inspired by a ‘role-switch’ analogy. The first (and second) model, namely ‘mRNA competition’ (and ‘miRNA competition’), takes into account the competitions among mRNAs (and miRNAs) for the same miRNA (and mRNA) using paired expression profile coupled with target site information (Figure <xref ref-type="fig" rid="F1">1</xref>). The third model ‘joint competition’ combines the former two predictions as joint probabilities. Using the expression data from (<xref rid="B10" ref-type="bibr">10</xref>) and The Cancer Genome Atlas (TCGA) (<xref rid="B11" ref-type="bibr">11</xref>), we first assess the proposed models as a target prediction tool by benchmarking the confidence or validated targets. The proposed models and the resulting probabilistic scores collectively termed as the <italic>Pro</italic>babilistic <italic>Mi</italic>RNA–mRNA <italic>I</italic>nteraction <italic>S</italic>ignatur<italic>e</italic> (ProMISe) confer competitive performance comparing with existing sequence- and regression-based methods. Furthermore, ProMISe signature exhibits competitive diagnostic power in discriminating normal/tumor profiles compared with using expression profiles alone. One explanation for the above observations is that ProMISe can capture complex MMIs not easily identified by examining expression profiles alone. For instance, some specific MMI changes in tumor are not only due to the expression changes of the corresponding miRNA/mRNA members but also due to the expression changes of the competing miRNAs and/or mRNAs. Moreover, genes with aberrant ProMISe signature are enriched for cancer-specific and oncomir-regulated gene sets based on gene set enrichment analysis (GSEA) (<xref rid="B12" ref-type="bibr">12</xref>). Some of the oncogenes with aberrant interactions do not exhibit significant expression changes. Thus, the inferred ProMISe signature can provide complementary information to the expression profiles. Integrative differential analysis of expression and ProMISe signature using matched tumor/normal samples from breast and thyroid cancers revealed many tumor-specific MMIs, involving canonical oncogenes and oncomirs. Together, our integrative approach bridges the aberrant miRNA and gene expression profiles with miRNA targeting mechanism, which enables us to explore cancer biology from a unique molecular perspective.</p>
    <fig id="F1" position="float">
      <label>Figure 1.</label>
      <caption>
        <p>The proposed competition model schema. (<bold>A</bold>) Expressed seed match of mRNA <italic>i</italic> for miRNA <italic>k</italic> is defined as the product of the number of target sites <italic>c</italic><sub><italic>i</italic>, <italic>k</italic></sub> and the total expression of mRNA <italic>i</italic>. The probability of mRNA <italic>i</italic> ‘attracting’ miRNA <italic>k</italic> takes into account the expression of miRNA <italic>k</italic> and the <italic>total</italic> expression of other mRNA
<inline-formula><tex-math id="M8">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\mathbf {x}}^{(t)}$\end{document}</tex-math></inline-formula> that carries compatible seed match for miRNA <italic>k.</italic> (<bold>B</bold>) Conversely, the expressed seed <italic>k</italic> for mRNA <italic>i</italic> is the number of target sites that miRNA <italic>k</italic> can recognize on mRNA <italic>i</italic> multiplied by the expression of miRNA <italic>k</italic>. The probability of miRNA <italic>k</italic> targeting mRNA <italic>i</italic> considers the ‘total’ expression of mRNA <italic>i</italic> and all of the other miRNA expression
<inline-formula><tex-math id="M9">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\mathbf {z}$\end{document}</tex-math></inline-formula> that can recognize the target sites of mRNA <italic>i</italic>. (<bold>C</bold>) A toy example. The inputs are 10 simulated mRNAs and 4 miRNA expression and a 10 × 4 seed-match matrix. ProMISe estimates the total mRNA expression based on the mRNA competition. It also infers the miRNA competition based on the total mRNA and the observed miRNA expression. The joint competition is the element-wise product of the above two matrices. Colored rectangles highlight some model properties explained in the main text.</p>
      </caption>
      <graphic xlink:href="gku182fig1"/>
    </fig>
  </sec>
  <sec sec-type="materials|methods" id="SEC2">
    <title>MATERIALS AND METHODS</title>
    <sec id="SEC2-1">
      <title>ProMISe</title>
      <p>We propose a novel probabilistic approach to infer probabilistic miRNA–mRNA interaction signature (ProMISe) using a ‘single’ pair of miRNA–mRNA expression profile. Assume we have <italic>N</italic> mRNAs and <italic>M</italic> miRNA. Let
<inline-formula><tex-math id="M10">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\mathbf{x}$\end{document}</tex-math></inline-formula> and
<inline-formula><tex-math id="M11">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\mathbf{z}$\end{document}</tex-math></inline-formula> be the observed mRNA and miRNA expression vectors, respectively, and
<inline-formula><tex-math id="M12">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\mathbf{C}$\end{document}</tex-math></inline-formula> be the <italic>N</italic> × <italic>M</italic> seed-match matrix, where <italic>c</italic><sub><italic>i</italic>, <italic>k</italic></sub> denotes the number of target sites on mRNA <italic>i</italic> for miRNA <italic>k</italic>. Assuming the cell is at a condition-specific equilibrium state, where mRNA are being dynamically transcribed and degraded (partly due to miRNA binding), then the <underline>t</underline>otal amount of transcribed mRNA targets
<inline-formula><tex-math id="M13">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\mathbf{x}^{(t)}$\end{document}</tex-math></inline-formula> are unobserved and higher than the <underline>o</underline>bserved (equilibrium) expression level
<inline-formula><tex-math id="M14">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\mathbf{x}^{(o)}$\end{document}</tex-math></inline-formula>. Our goal is to infer
<inline-formula><tex-math id="M15">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$p(t_{i,k} | \mathbf {x}^{(t)}, \mathbf {z}^{(t)}, \mathbf{C})$\end{document}</tex-math></inline-formula> for whether miRNA <italic>k</italic> targets mRNA <italic>i</italic>, given the (hidden) total transcription levels of mRNA and miRNA. Notably,
<inline-formula><tex-math id="M16">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\mathbf {z}^{(t)} = \mathbf {z}^{(o)} \equiv \mathbf{z}$\end{document}</tex-math></inline-formula>, assuming that the observed miRNA expression is the same as its total transcribed levels. Thus, we drop the superscript for
<inline-formula><tex-math id="M17">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\mathbf{z}$\end{document}</tex-math></inline-formula> in the following formulation. Here we estimate
<inline-formula><tex-math id="M18">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$p(t_{i,k} | \mathbf {x}^{(t)}, \mathbf {z}^{(t)}, \mathbf{C})$\end{document}</tex-math></inline-formula> by three related models reflecting mRNA competition, miRNA competition, and joint competition, respectively. Let
<inline-formula><tex-math id="M19">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\mathbf{c}_{.,k}$\end{document}</tex-math></inline-formula> and
<inline-formula><tex-math id="M20">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\mathbf{c}_{i,.}$\end{document}</tex-math></inline-formula> denote the number of target sites of each mRNA for miRNA <italic>k</italic> and the number of target sites that mRNA <italic>i</italic> has for each miRNA, respectively. In the mRNA competition model, we express
<inline-formula><tex-math id="M21">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$p(t^{(x)}_{i,k} | \mathbf {x}^{(t)}, z_k, \mathbf{c}_{.,k})$\end{document}</tex-math></inline-formula> as the probability of mRNA <italic>i</italic> ‘attracting’ miRNA <italic>k</italic>, given the expression of all of the mRNAs that miRNA <italic>k</italic> can target according to
<inline-formula><tex-math id="M22">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\mathbf{c}_{.,k}$\end{document}</tex-math></inline-formula> (Figure <xref ref-type="fig" rid="F1">1A</xref>). Thus, it reflects the <italic>mRNA competition</italic> for the same miRNA. Specifically, the probability that mRNA <italic>i</italic> attracting a specific miRNA <italic>k</italic> is calculated as the reversed probability that miRNA <italic>k</italic> is attracted by other mRNA <italic>j</italic> (<italic>j</italic> ≠ <italic>i</italic>):
<disp-formula id="M1"><label>(1)</label><tex-math id="M23">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}
\begin{equation*}
p(t^{(x)}_{i,k} | {\bf x}^{(t)}, z_k, {\bf c}_{.,k}) = 1 - \left[\frac{\sum _{j\ne i}c_{j,k}x_j^{(t)}}{\sum _{j^{\prime }} c_{j^{\prime },k}x_{j^{\prime }}^{(t)}}\right]^{z_k}.
\end{equation*}
\end{document}</tex-math></disp-formula>Note the use of the exponent
<inline-formula><tex-math id="M24">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$ z$\end{document}</tex-math></inline-formula><sub><italic>k</italic></sub> from Equation (<xref ref-type="disp-formula" rid="M1">1)</xref> to reflect that the higher the miRNA <italic>k</italic> expressed the more likely it will be attracted to mRNA <italic>i</italic>. Conversely, the miRNA competition model
<inline-formula><tex-math id="M25">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$p(t^{(z)}_{i,k} | x_i^{(t)}, {\bf z}, \mathbf{c}_{i,.})$\end{document}</tex-math></inline-formula> reflects the probability that miRNA <italic>k</italic> targets mRNA <italic>i</italic>, taking into account the expression of all of the miRNAs that can target mRNA <italic>i</italic> according to
<inline-formula><tex-math id="M26">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\mathbf{c}_{i,.}$\end{document}</tex-math></inline-formula> (Figure <xref ref-type="fig" rid="F1">1B</xref>). The probability that miRNA <italic>k</italic> targeting a particular mRNA <italic>i</italic> is calculated as the reversed probability that mRNA <italic>i</italic> is targeted by other miRNA <italic>l</italic> (<italic>l</italic> ≠ <italic>k</italic>):
<disp-formula id="M2"><label>(2)</label><tex-math id="M27">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}
\begin{equation*} p(t^{(z)}_{i,k} | x_i^{(t)}, {\bf z}, {\bf c}_{i,.}) = 1 - \left[\frac{\sum _{l\ne k}c_{i,l}z_l}{\sum _{l^{\prime }} c_{i,l^{\prime }}z_{l^{\prime }}}\right]^{x_i^{(t)}}.
\end{equation*}
\end{document}</tex-math></disp-formula>Thus, the first and second models respectively reflect the ‘dilution-effects’ of multiple mRNAs targeted by the same miRNA or the mRNA competition (<xref rid="B9" ref-type="bibr">9</xref>) and the competition among miRNAs for the same mRNA (<xref rid="B13" ref-type="bibr">13</xref>). Finally, we express the joint competition as
<inline-formula><tex-math id="M28">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$p(t_{i,k}^{(j)} | \mathbf {x}^{(t)}, \mathbf {z}, \mathbf{C})$\end{document}</tex-math></inline-formula>:
<disp-formula id="M3"><label>(3)</label><tex-math id="M29">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}
\begin{equation*} p(t_{i,k}^{(j)} | \mathbf {x}^{(t)}, \mathbf {z}, \mathbf {C}) = p(t^{(x)}_{i,k} | \mathbf {x}^{(t)}, z_k, \mathbf {c}_{.,k}) p(t^{(z)}_{i,k} | x_i^{(t)}, \mathbf {z}, \mathbf {c}_{i,.}).
\end{equation*}
\end{document}</tex-math></disp-formula>Notably, an underlying assumption of Equation <xref ref-type="disp-formula" rid="M3">(3</xref>) is that mRNA competition and miRNA completion are independent events. Algorithmically, we estimate Equations <xref ref-type="disp-formula" rid="M1">(1</xref>–<xref ref-type="disp-formula" rid="M3">3)</xref> together in two phases. As initialization, we set
<inline-formula><tex-math id="M30">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\mathbf {x}^{(t)} = \mathbf{x}^{(o)}$\end{document}</tex-math></inline-formula>. We first estimate Equation (<xref ref-type="disp-formula" rid="M1">1</xref>). Given Equation (<xref ref-type="disp-formula" rid="M1">1</xref>), the expected reduction level due to miRNA <italic>k</italic> binding is estimated as
<disp-formula id="M4"><label>(4)</label><tex-math id="M31">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}
\begin{equation*} \Delta x_{i,k} = \eta p(t^{(x)}_{i,k} | \mathbf {x}^{(t)}, z_k, \mathbf {c}_{.,k}) x_i^{(t)},
\end{equation*}
\end{document}</tex-math></disp-formula>where η is the ‘learning rate’ (default: 0.001). Given Δ<italic>x</italic><sub><italic>i</italic>, <italic>k</italic></sub>, the total transcribed mRNA is updated in two steps as follows:
<disp-formula id="M5"><label>(5)</label><tex-math id="M32">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}
\begin{equation*} x_i^{(t)*} = x_i^{(t)} + \sum _k\Delta x_{i,k}
\end{equation*}
\end{document}</tex-math></disp-formula>
<disp-formula id="M6"><label>(6)</label><tex-math id="M33">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}
\begin{equation*} x_i^{(t)} = \frac{x_i^{(t)*}}{\sum _ix_i^{(t)*}}T,
\end{equation*}
\end{document}</tex-math></disp-formula>where Equation (<xref ref-type="disp-formula" rid="M5">5</xref>) reflects the total reduction of mRNA <italic>i</italic> by each miRNA and <italic>T</italic> defines the transcriptional capacity of the cell (default:
<inline-formula><tex-math id="M34">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$T = 1.3 \sum x_i^{(o)}$\end{document}</tex-math></inline-formula>, where 1.3 is an arbitrary value that reflects the total transcribed mRNA ‘before’ miRNA repression). We then estimate Equation (<xref ref-type="disp-formula" rid="M2">2</xref>). The model alternates between estimating (<xref ref-type="disp-formula" rid="M1">1</xref>) and (<xref ref-type="disp-formula" rid="M2">2</xref>) until
<inline-formula><tex-math id="M35">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$p(t^{(x)}_{i,k} | \mathbf {x}^{(t)}, z_k, \mathbf{c}_{.,k})$\end{document}</tex-math></inline-formula> and
<inline-formula><tex-math id="M36">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$p(t^{(z)}_{i,k} | x_i^{(t)}, \mathbf {z}, \mathbf{c}_{i,.})$\end{document}</tex-math></inline-formula> increase by less than a threshold (tol) (default: 10<sup>−5</sup>) at <italic>t</italic><sup>th</sup> iteration:
<disp-formula><tex-math id="M37">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}\begin{eqnarray*} \max \left[\left| p(t^{(x)}_{i,k} | \mathbf {x}^{(t)}, z_k, \mathbf {c}_{.,k})^t - p(t^{(x)}_{i,k} | \mathbf {x}^{(t)}, z_k, \mathbf {c}_{.,k})^{t-1} \right|\right] \le {\rm tol} \\ \max \left[\left| p(t^{(z)}_{i,k} | x_i^{(t)}, \mathbf {z}, \mathbf {c}_{i,.})^t - p(t^{(z)}_{i,k} | x_i^{(t)}, \mathbf {z}, \mathbf {c}_{i,.})^{t-1} \right|\right] \le {\rm tol}. \end{eqnarray*}\end{document}</tex-math></disp-formula></p>
    </sec>
    <sec id="SEC2-2">
      <title>Target site information</title>
      <p>We downloaded human target site information from TargetScanHuman 6.2 database (<xref rid="B14" ref-type="bibr">14</xref>). For each mRNA–miRNA pair, we calculated the number of corresponding conserved target sites. For multiple transcripts of the same gene, we used transcripts with the longest 3′UTR. The end result is an <italic>N</italic> × <italic>M</italic> seed-match matrix of <italic>N</italic> distinct mRNAs each corresponding to a distinct gene and <italic>M</italic> distinct miRNAs. We also obtained the context+ scores (CS) (<xref rid="B15" ref-type="bibr">15</xref>) and probability of conserved targeting (PCT) (<xref rid="B14" ref-type="bibr">14</xref>) as sequence-based scores for comparison.</p>
    </sec>
    <sec id="SEC2-3">
      <title>HEK293 test set and power analysis</title>
      <p>Gene and miRNA expression from HEK293 as measured by serial analysis of gene expression (SAGE) and small RNA-seq were obtained from (<xref rid="B10" ref-type="bibr">10</xref>). We constructed the positive and negative target sets from the PAR-CLIP and microarray data generated by (<xref rid="B10" ref-type="bibr">10</xref>) following similar way described in (<xref rid="B16" ref-type="bibr">16</xref>). We first downloaded from doRiNAdb (<xref rid="B17" ref-type="bibr">17</xref>) the confidence AGO2 targets identified from PAR-CLIP data in the same study. We then downloaded from Gene Expression Omnibus (GEO) (GSE21577) the microarray data measuring gene expression in HEK293 after treated with mock control or a cocktail chemistry inhibiting 27 most highly expressed miRNA in HEK293. The true targets of the 27 miRNA are expected to exhibit increased expression level upon miRNA inhibition. Thus, the confidence positive targets were defined as the genes that are AGO2 targets, have at least one seed match to the 27 miRNA, and exhibit fold-change greater than 0.1. To create a confidence set of non-targets, we selected the same number of genes that are not AGO2 targets and exhibit non-positive fold-changes with priority given to genes with decreased expression. We then assessed the accuracy of the methods using receiver operating characteristic (ROC) and precision-recall curves (PRCs) (<xref rid="B18" ref-type="bibr">18</xref>) (details described in the simulation tests in Supplementary Data).</p>
    </sec>
    <sec id="SEC2-4">
      <title>TCGA data collection and processing</title>
      <p>Expression data were downloaded from TCGA Data Portal (<ext-link ext-link-type="uri" xlink:href="https://tcga-data.nci.nih.gov">https://tcga-data.nci.nih.gov</ext-link>). Only the processed data (level 3) were used. To date, there are 10 cancer types that are associated with data both unrestricted for publication and containing paired miRNA and mRNA expression (Table <xref ref-type="table" rid="T1">1</xref>). Except for glioblastoma multiforme (GBM) and ovarian serous cystadenocarcinoma (OV), for which the microarray data were used, RNA-seq(V2) and miRNA-seq were used for mRNA and miRNA expression data, respectively. Normal/tumor information for each sample were obtained from Biospecimen Metadata Browser (<ext-link ext-link-type="uri" xlink:href="https://tcga-data.nci.nih.gov/uuid/uuidBrowser.htm">https://tcga-data.nci.nih.gov/uuid/uuidBrowser.htm</ext-link>) and mapped based on the sample ID. For the sequencing data, we used the RPKM (read per kilobase of exon per million mapped reads) values for mRNA and RPM (reads per million miRNA mapped) for miRNA. To ensure individual samples are comparable, we further quantile normalized the RPKM and RPM values within each disease type.</p>
      <table-wrap id="T1" position="float">
        <label>Table 1.</label>
        <caption>
          <p>Paired expression data from TCGA</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th align="left" rowspan="1" colspan="1">Cancer</th>
              <th align="left" rowspan="1" colspan="1">mRNA</th>
              <th align="left" rowspan="1" colspan="1">miRNA</th>
              <th align="left" rowspan="1" colspan="1">Normal</th>
              <th align="left" rowspan="1" colspan="1">Tumor</th>
              <th align="left" rowspan="1" colspan="1">Total</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" rowspan="1" colspan="1">BRCA</td>
              <td align="left" rowspan="1" colspan="1">13306</td>
              <td align="left" rowspan="1" colspan="1">710</td>
              <td align="left" rowspan="1" colspan="1">14</td>
              <td align="left" rowspan="1" colspan="1">317</td>
              <td align="left" rowspan="1" colspan="1">331</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">COAD</td>
              <td align="left" rowspan="1" colspan="1">13306</td>
              <td align="left" rowspan="1" colspan="1">710</td>
              <td align="left" rowspan="1" colspan="1">0</td>
              <td align="left" rowspan="1" colspan="1">177</td>
              <td align="left" rowspan="1" colspan="1">177</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">GBM</td>
              <td align="left" rowspan="1" colspan="1">10344</td>
              <td align="left" rowspan="1" colspan="1">338</td>
              <td align="left" rowspan="1" colspan="1">10</td>
              <td align="left" rowspan="1" colspan="1">496</td>
              <td align="left" rowspan="1" colspan="1">506</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">HNSC</td>
              <td align="left" rowspan="1" colspan="1">13306</td>
              <td align="left" rowspan="1" colspan="1">710</td>
              <td align="left" rowspan="1" colspan="1">0</td>
              <td align="left" rowspan="1" colspan="1">37</td>
              <td align="left" rowspan="1" colspan="1">37</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">KIRC</td>
              <td align="left" rowspan="1" colspan="1">13306</td>
              <td align="left" rowspan="1" colspan="1">710</td>
              <td align="left" rowspan="1" colspan="1">0</td>
              <td align="left" rowspan="1" colspan="1">274</td>
              <td align="left" rowspan="1" colspan="1">274</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">LUSC</td>
              <td align="left" rowspan="1" colspan="1">13306</td>
              <td align="left" rowspan="1" colspan="1">710</td>
              <td align="left" rowspan="1" colspan="1">0</td>
              <td align="left" rowspan="1" colspan="1">132</td>
              <td align="left" rowspan="1" colspan="1">132</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">OV</td>
              <td align="left" rowspan="1" colspan="1">8371</td>
              <td align="left" rowspan="1" colspan="1">542</td>
              <td align="left" rowspan="1" colspan="1">8</td>
              <td align="left" rowspan="1" colspan="1">565</td>
              <td align="left" rowspan="1" colspan="1">573</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">READ</td>
              <td align="left" rowspan="1" colspan="1">13306</td>
              <td align="left" rowspan="1" colspan="1">710</td>
              <td align="left" rowspan="1" colspan="1">0</td>
              <td align="left" rowspan="1" colspan="1">66</td>
              <td align="left" rowspan="1" colspan="1">66</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">THCA</td>
              <td align="left" rowspan="1" colspan="1">13306</td>
              <td align="left" rowspan="1" colspan="1">710</td>
              <td align="left" rowspan="1" colspan="1">58</td>
              <td align="left" rowspan="1" colspan="1">485</td>
              <td align="left" rowspan="1" colspan="1">543</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">UCEC</td>
              <td align="left" rowspan="1" colspan="1">13306</td>
              <td align="left" rowspan="1" colspan="1">710</td>
              <td align="left" rowspan="1" colspan="1">1</td>
              <td align="left" rowspan="1" colspan="1">124</td>
              <td align="left" rowspan="1" colspan="1">125</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="T1TFN1">
            <p>BRCA: breast cancer; COAD: colon adenocarcinoma; GBM: glioblastoma multiforme; HNSC: head and neck squamous cell carcinoma; KIRC: clear cell carcinoma; LUSC: lung squamous cell carcinoma; OV: ovarian serous cystadenocarcinoma; READ: rectal adenocarcinoma; THCA: thyroid carcinoma; UCEC: uterine corpus endometrial carcinoma.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec id="SEC2-5">
      <title>Validated miRNA targets, oncogenes, oncomirs, OMIM genes and cancer gene hubs</title>
      <p>Validated targets were downloaded from MirTarBase 3.5 (<xref rid="B19" ref-type="bibr">19</xref>), the oncogenes from COSMIC (<xref rid="B20" ref-type="bibr">20</xref>), the oncomirs from (<xref rid="B3" ref-type="bibr">3</xref>) and OMIM (Online Mendelian Inheritance in Man) genes from <ext-link ext-link-type="uri" xlink:href="http://www.omim.org/">http://www.omim.org/</ext-link>. Putative cancer gene hubs, which are discriminative of luminal and basal subtypes of 16 breast cancer cell lines, were obtained from (<xref rid="B21" ref-type="bibr">21</xref>).</p>
    </sec>
    <sec id="SEC2-6">
      <title>Methods of comparison</title>
      <p>We compared ProMISe constructed from the three proposed competition models with six methods, namely Seed Matrix containing conserved target sites from TargetScan, TargetScan PCT, TargetScan Context Score, Pearson correlation, LASSO and GenMiR++. For Seed Matrix and TargetScan PCT/context score, which do not consider expression data, the mRNA–miRNA interactions were simply ranked by the corresponding number of target sites and specific scores. To be fair, we filtered out interactions involving non-expressed miRNA beforehand. Pearson correlation was computed using R built-in function <monospace>cor</monospace>. Here targets with negative correlation were ranked at the top. We implemented LASSO using <italic>glmnet</italic> with default parameters (i.e. α = 1 for LASSO) except that the best λ was chosen using cross-validation function <monospace>cv.glmnet</monospace> (<xref rid="B22" ref-type="bibr">22</xref>). The predictors in the LASSO model are the miRNA expression multiplied by the seed-match matrix. Thus, the expression of a miRNA has no effect on mRNA expression if the corresponding seed-matrix entry is zero. Here again targets with negative linear coefficients are ranked at the top. To run GenMiR++ (<xref rid="B5" ref-type="bibr">5</xref>) in Matlab, we converted the above seed matrix to binary matrix by setting nonzero target site count to 1. Due to the lack of validated targets, conventional ROC and PRC approaches cannot distinguish the method performances on TCGA data. Instead, we assessed each method by the number of validated targets in their top ranked 500–2000 targets with 500-interval (Figure <xref ref-type="fig" rid="F2">2</xref>).</p>
      <fig id="F2" position="float">
        <label>Figure 2.</label>
        <caption>
          <p>Identification of confidence or validated targets. (<bold>A</bold>) Based on positive/negative targets and the prediction scores, ROC and PRC were generated for the six methods, where Seed Matrix, TargetScan Context Score and PCT are sequence-based and the other three are proposed competition models. (<bold>B</bold>) The number of validated targets selected by each method among their top 1000 rankings as a function of sample. Ten panels correspond to 10 cancer types. The curves are smoothed using <monospace>loess</monospace> from R function <monospace>geom_smooth</monospace>. (<bold>C</bold>) Comparison of the competition models with other expression-based methods including Pearson correlation, LASSO and GenMiR++.</p>
        </caption>
        <graphic xlink:href="gku182fig2"/>
      </fig>
    </sec>
    <sec id="SEC2-7">
      <title>Unsupervised learning on cancer data</title>
      <p>Hierarchical clustering was applied to expression profiles or ProMISe signature using R function <monospace>hclust</monospace> (Figure <xref ref-type="fig" rid="F3">3A</xref>, Supplementary Figure S5). One minus Pearson correlation and average linkage were used.</p>
      <fig id="F3" position="float">
        <label>Figure 3.</label>
        <caption>
          <p>Cancer diagnosis. (<bold>A</bold>) Hierarchical clustering of expression or ProMISe signature for thyroid cancer. Red and blue colors indicate tumor and normal samples, respectively. (<bold>B</bold>) Regularized logistic regression was applied to classify normal and thyroid cancer tumor profiles using expression or ProMISe signature. Mean cross entropy (MCE) from LOOCV was used to assess the performance of each method. Superior method confers lower MCE and thus higher −log10(MCE).</p>
        </caption>
        <graphic xlink:href="gku182fig3"/>
      </fig>
    </sec>
    <sec id="SEC2-8">
      <title>Supervised learning on cancer data</title>
      <p>To classify samples into normal and cancer, we employed regularized logistic regression with L1/L2-norm using R package <italic>glmnet</italic> (<xref rid="B22" ref-type="bibr">22</xref>). Specifically, we trained a linear model with α = 0.5 on training set using gene expression, miRNA expression, combined expression or ProMISe signature from the three competition models. In each training process, the only free parameter λ was determined by 10-fold cross-validation using <monospace>cv.glmnet</monospace>. The performances of the trained models on the training and testing set were rigorously evaluated by leave-one-out cross-validation (LOOCV) in terms of mean cross entropy (MCE) error:
<disp-formula id="M7"><label>(7)</label><tex-math id="M38">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}
\begin{equation*} {\rm MCE} = \frac{1}{N}\sum _{n=1}^N -t_n \log p_n
\end{equation*}
\end{document}</tex-math></disp-formula>where <italic>t</italic> is a binary indicator for tumor (1) or normal (0) and <italic>p</italic> is the predictive probability from the logistic regression model for sample <italic>n</italic> of being tumor. Thus, MCE is small if both <italic>t</italic><sub><italic>n</italic></sub> and <italic>p</italic><sub><italic>n</italic></sub> are high or low at the same time and large when <italic>t</italic><sub><italic>n</italic></sub> is high and <italic>p</italic><sub><italic>n</italic></sub> is small. We applied LOOCV to THCA, which has at least 10% normal samples (Table <xref ref-type="table" rid="T1">1</xref>). Figure <xref ref-type="fig" rid="F3">3B</xref> displays the resulting MCE in barplots.</p>
    </sec>
    <sec id="SEC2-9">
      <title>Permutation tests</title>
      <p>The normal and tumor samples in THCA are not balanced (58 normals versus 485 tumors), which may lead to overestimation of model performance in terms of the MCE (Equation (<xref ref-type="disp-formula" rid="M7">7))</xref>. To assess the classifiers’ performances more rigorously, we conducted 100 permutation tests by randomly swapping values between normal and tumor samples and repeating the above LOOCV for each type of biomarkers. The empirical <italic>p</italic>-value of the permutation test is defined as the fraction of tests having MCE as least as good as the MCE derived from the real test.</p>
    </sec>
    <sec id="SEC2-10">
      <title>Gene set enrichment analysis</title>
      <p>We applied GSEA (2.0.13) to both gene expression and genes with averaged ProMISe signature across miRNAs (<xref rid="B12" ref-type="bibr">12</xref>). Default setting was used. Gene sets were downloaded from the Molecular Signatures Database (MSigDB) (<ext-link ext-link-type="uri" xlink:href="http://www.broadinstitute.org/gsea/msigdb/index.jsp">http://www.broadinstitute.org/gsea/msigdb/index.jsp)</ext-link>. The maximum and minimum number of genes allowed in each gene set was set to 5000 and 15, respectively.</p>
    </sec>
    <sec id="SEC2-11">
      <title>Paired sample comparison</title>
      <p>Paired <italic>t</italic>-test (<monospace><italic>t</italic>.test(…, paired = <italic>T</italic>)</monospace> in R) was performed to compare quantile normalized ProMISe or expression profiles from the 14 and 58 matched tumor/normal samples in BRCA and THCA, respectively.</p>
    </sec>
    <sec id="SEC2-12">
      <title>Software availability</title>
      <p>ProMISe was implemented as an R package available at Bioconductor: <ext-link ext-link-type="uri" xlink:href="http://www.bioconductor.org/packages/release/bioc/html/Roleswitch.html">www.bioconductor.org/packages/release/bioc/html/Roleswitch.html</ext-link>.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="SEC3">
    <title>RESULTS</title>
    <sec id="SEC3-1">
      <title>ProMISe</title>
      <p>The proposed model takes as inputs the paired mRNA and miRNA expression and the seed-match matrix. It then estimates the probabilities of different mRNA ‘attracting’ the same miRNA (i.e. mRNA competition; Figure <xref ref-type="fig" rid="F1">1A</xref>, Equation (<xref ref-type="disp-formula" rid="M1">1)</xref>), the probabilities of different miRNA targeting the same mRNA (i.e. miRNA competition; Figure <xref ref-type="fig" rid="F1">1B</xref>, Equation <xref ref-type="disp-formula" rid="M2">(2)</xref>), and the element-wise products of the above two (i.e. joint competition; Equation (<xref ref-type="disp-formula" rid="M3">3)</xref>). To highlight several important features of the proposed model, Figure <xref ref-type="fig" rid="F1">1C</xref> illustrates a toy example using simulated data of 10 mRNAs and 4 miRNAs. First, mRNA <italic>i</italic> that does not carry a seed match for miRNA <italic>k</italic> has zero probability of being its target (e.g. mRNA 1 and miRNA 2) (see Discussion section for other possibilities). Second,
<inline-formula><tex-math id="M39">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$p(t^{(x)}_{i,k} | \mathbf {x}^{(t)}, z_k, \mathbf{c}_{.,k})$\end{document}</tex-math></inline-formula> (mRNA competition) and
<inline-formula><tex-math id="M40">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$p(t^{(z)}_{i,k} | x_i^{(t)}, \mathbf {z}, \mathbf{c}_{i,.})$\end{document}</tex-math></inline-formula> (miRNA competition) differ for the same pair of miRNA and mRNA. For instance,
<inline-formula><tex-math id="M41">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$p(t^{(x)}_{2,4} | \mathbf {x}^{(t)}, z_4, \mathbf{c}_{.,4}) = 0.26$\end{document}</tex-math></inline-formula> and
<inline-formula><tex-math id="M42">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$p(t^{(z)}_{2,4} | x_1^{(t)}, \mathbf {z}, \mathbf{c}_{2,.}) = 1$\end{document}</tex-math></inline-formula>. Intuitively, mRNA 2 has only one target site for miRNA 4, which can potentially target many other mRNAs (vertical red boxes) such as mRNA 1 and 3, that each has higher expression level, two target sites, and thus higher probabilities of being targeted by miRNA 4. On the other hand, mRNA 2 can only ‘attract’ miRNA 4 because none of the other three miRNAs recognizes its target site (horizontal blue boxes), which explains
<inline-formula><tex-math id="M43">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$p(t^{(z)}_{2,4} | x_2^{(t)}, \mathbf {z}, \mathbf{c}_{2,.}) = 1$\end{document}</tex-math></inline-formula>. Third, the joint competition model (Equation (<xref ref-type="disp-formula" rid="M3">3)</xref>) provides a conservative estimate, for which both miRNA and mRNA competition scores must be high to confer a high confidence prediction (e.g. mRNA 10 and miRNA 2). The model converges quickly in only a few iterations for large number of mRNAs and miRNAs (Supplementary Figure S1). To rigorously test the models, we designed four scenarios (Supplementary Figure S2). Below we compared ProMISe with other methods using real expression data.</p>
    </sec>
    <sec id="SEC3-2">
      <title>Target predictions</title>
      <p>We first compared ProMISe with sequence-based methods in discriminating the 1255 confidence positive and negative targets identified from HEK293 using the published data by (<xref rid="B10" ref-type="bibr">10</xref>) (Materials and Methods section). We chose TargetScan Context Score (<xref rid="B15" ref-type="bibr">15</xref>) and Probabilities of Conserved Targeting (PCT) (<xref rid="B14" ref-type="bibr">14</xref>) as the representative sequence-based methods based on our recent evaluations (<xref rid="B4" ref-type="bibr">4</xref>). We observed excellent Area Under the ROC Curve (AUROC) from all three proposed competition models (Figure <xref ref-type="fig" rid="F2">2A</xref>, left). In particular, the joint and mRNA competition models confer the highest AUROC (99.7%), which is 1–6% higher than the sequence-based methods. Additionally, we observed even better performance from the competition models in terms of precision recall (Figure <xref ref-type="fig" rid="F2">2A</xref>, right) with 19.4–45.9% improvements over the sequence-based methods. Interestingly, the mRNA competition model outperforms the joint and miRNA competition models by 0.4% and 7%, respectively. We next evaluated each model on the TCGA data. To further take advantage of the sequence information, we multiplied ProMISe with the TargetScan PCT. To be fair with the sequence-based methods, we filtered out interactions involving miRNAs that are not expressed in each sample beforehand. Each panel in Figure <xref ref-type="fig" rid="F2">2B</xref> depicts the number of validated targets among the top 1000 ranking as a function of sample ID. The ProMISe constructed from the mRNA competition model demonstrated clearly superior performances over other methods in identifying validated MMIs (Figure <xref ref-type="fig" rid="F2">2B</xref>). The joint competition model achieves similar performances as the mRNA competition model. Moreover, we observed consistent results using the top rankings from 500 to 2000 with 500-increment (Supplementary Figure S3). We then compared ProMISe with three other expression-based methods, namely Pearson correlation, LASSO regression (<xref rid="B6" ref-type="bibr">6)</xref> and GenMiR++ (<xref rid="B5" ref-type="bibr">5</xref>). Because ProMISe confers good pairwise correlation between individual samples (Supplementary Figure S4), the averaged ProMISe signature over all samples was used for each cancer type. All three competition models demonstrated superior performances in 9 out of the 10 cancer types while the mRNA or joint competition models achieve higher performance than the miRNA competition model (Figure <xref ref-type="fig" rid="F2">2C</xref>). Thus, ProMISe compares favorably with the existing methods, and yet has the unique advantage of constructing ProMISe signature from each individual sample.</p>
    </sec>
    <sec id="SEC3-3">
      <title>Cancer diagnosis</title>
      <p>We examined whether using the ProMISe signature can discriminate tumors from normal samples in comparison with using expression profiles. We first performed hierarchical clustering as an unsupervised approach. Indeed, for each cancer type ProMISe from all three competition models cluster based on normal (blue) and tumor (red) (Supplementary Figure S5). For instance, clustering of thyroid cancer data, which consist of 58 normals and 485 tumors, is more consistent with the underlying phenotypes than clustering by expression (Figure <xref ref-type="fig" rid="F3">3B</xref>). We then performed regularized logistic regression on THCA and evaluated the testing accuracy by MCE error from LOOCV. As shown in Figure <xref ref-type="fig" rid="F3">3B</xref>, the mRNA and joint competition models achieve the lowest MCE, which is significantly better than randomized data based on permutation test (<italic>p</italic> &lt; 0.01). Notably, however, the performances of each model on individual test cases tend to vary due to the heterogeneity of the tumor samples (Supplementary Figure S6). The effects of resampling on biomarker robustness and rigorous counter-strategies have been demonstrated by Li <italic>et al.</italic> (<xref rid="B23" ref-type="bibr">23</xref>). As a simple remedy, we focused our comparison on the matched tumor/normal samples to mitigate such effects in deriving tumor-specific MMIs in sections below. Together, the additional leverage provided by ProMISe over the (combined) expression data suggests that our integrative approach of modeling MMI provides useful diagnostic information complementary to the expression profile signatures. In the following analyses, we used the mRNA competition model to represent ProMISe.</p>
    </sec>
    <sec id="SEC3-4">
      <title>GSEA on ProMISe signature uniquely revealed abnormal activities of miR-21 and miR-145 in GBM and OV</title>
      <p>Aberrant miRNA and mRNA expressions have long been implicated in some specific cancer phenotypes (<xref rid="B3" ref-type="bibr">3</xref>). To examine whether miRNA-dysregulated genes (MDGs) are enriched for meaningful gene sets, we averaged ProMISe signature of each gene over all of the miRNAs. Surprisingly, we not only recovered cancer-specific but also oncomir-specific target gene sets with false discovery rate (FDR) &lt;0.05 (Supplementary Table S1). In particular, synaptic transmission (MSigDB ID: M19659), psychiatric disorders (M2110), medulloblastoma (M16478), neuron cell-type specificity (M1712) and human brain aging (M9112) are among the top 10 ranked gene sets with lower ProMISe in GBM. On the other hand, gene set corresponding to the predicted miR-21 targets (M19659) ranks the second among those exhibiting higher ProMISe in GBM (Figure <xref ref-type="fig" rid="F4">4A</xref>, left). Previous studies have shown that the increased expression of miR-21 causes downregulation of tumor suppressor PDCD4, which stimulates cell growth across GBM cell lines (<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B24" ref-type="bibr">24</xref>). Indeed, we observed an increased ProMISe and a coherent decreased PDCD4 expression in tumor (Figure <xref ref-type="fig" rid="F4">4A</xref>, right). Additionally, miR-21 also regulates RECK and TIMP3 to promote anti-apoptosis and migration of GBM cells (<xref rid="B24" ref-type="bibr">24</xref>). Notably, both ProMISe and expression for genes RECK and TIMP3 have increased in GBM tumors, which is in fact consistent with our intuition that the higher the miRNA/mRNA abundance the more likely they interact with each other. We applied the same analysis to ovarian cancer and discovered an over-representation of miR-145 target set (M15956), ranking third among the gene sets with lower ProMISe in OV. Indeed, miR-145 is downregulated in OV and its targets confirmed by luciferase reporter assays include CBFB, PPP3CA and CLINT1 (<xref rid="B25" ref-type="bibr">25</xref>). Notably, CLINT1 has an increased expression and decreased ProMISe (Figure <xref ref-type="fig" rid="F4">4B</xref>)(<xref rid="B26" ref-type="bibr">26</xref>).</p>
      <fig id="F4" position="float">
        <label>Figure 4.</label>
        <caption>
          <p>Gene set enrichment analysis. GSEA was applied to the averaged ProMISe signature of each gene over all of the miRNAs in tumor versus normal comparison (<xref rid="B12" ref-type="bibr">12</xref>). Enriched gene sets corresponding to miR-21 and miR-145 targets were identified from the GBM and OV data, respectively. The enriched gene sets for GBM (OV) has its gene members accumulated at the top of the list ranked by ProMISe signature changes in tumor versus normal (normal versus tumor). The right panels illustrate the network view of specific miRNA targets. The filled color in the node corresponds to expression log2 fold-change in tumor, where red (blue) indicates increased (decreased) gene/miRNA expression. The edge color and width captures the ProMISe signature changes as Signal/Noise ratio as calculated by GSEA, where red (blue) indicates increased (decreased) ProMISe signature in tumor. The network was generated using Cytoscape (<xref rid="B26" ref-type="bibr">26</xref>).</p>
        </caption>
        <graphic xlink:href="gku182fig4"/>
      </fig>
    </sec>
    <sec id="SEC3-5">
      <title>ProMISe-predicted MDGs in tumors are enriched for canonical cancer genes and cancer genes hubs</title>
      <p>Using the 14 matched tumor/normal samples from TCGA-BRCA data, we performed paired <italic>t</italic>-test to obtain differential ProMISe signature and mRNA/miRNA expression in tumor versus normal. In total, 23 797 out of 56 805 MMIs exhibit significant changes in ProMISe at FDR &lt; 0.05 (Figure <xref ref-type="fig" rid="F5">5A</xref>), which involve 5690 out of 13035 and 103 out of 710 distinct MDGs and miRNAs, respectively. At the same cutoff, we obtained 3073 and 40 differentially expressed genes (DEGs) and miRNA. We then assessed the overlap between the DEGs and MDGs and their overlaps with the putative cancer gene hubs from (<xref rid="B21" ref-type="bibr">21</xref>). As illustrated in the Venn diagram (Figure <xref ref-type="fig" rid="F5">5C</xref>), the DEGs are significantly enriched for MDGs (p &lt; 1e-447, Hypergeometric test). However, 3285 MDGs are not DEGs, and 681 DEGs are not MDGs. Moreover, MDGs are significantly enriched for cancer gene hubs: 18 out of the 21 genes have abnormal ProMISe signature in tumor (p &lt;10<sup>−5</sup>, Hypergeometric test). In contrast, only 5 cancer gene hubs exhibit aberrant expression (p &lt; 1). We repeated the same analysis on 58 matched tumor/normal samples for thyroid cancer (THCA) to obtain 35 453 out of 86 923 significant interactions at FDR &lt; 0.005 (Figure <xref ref-type="fig" rid="F5">5B</xref>), involving 6780 (113) MDGs (miRNA) and 4778 (58) DEGs (miRNA). Twenty of the cancer gene hubs exhibit abnormal interaction with miRNAs (<italic>p</italic> &lt; 10<sup>−6</sup>) but only 13 of them have differential expression (Figure <xref ref-type="fig" rid="F5">5D</xref>). Moreover, we compared DEGs and MDGs in both cancers with cancer-related genes from OMIM and obtained consistent results (Supplementary Figure S7). Thus, genes with differential MMIs may not have aberrant expression in tumor and vice versa. It is possible that some of the tumor-related genes are more strongly regulated at the translational levels. In that case, our approach is still able to detect at least some of these translationally regulated genes since ProMISe exploits not only the gene expression but also the miRNA expression as well as the sequence information. Moreover, the variability of gene expression profiles between individual tumors can be extremely high, which leads to low detection power of the true cancer signals using gene expression alone (<xref rid="B23" ref-type="bibr">23</xref>). Together, the results suggest that we have gained statistical power by identifying more cancer-related genes using ProMISe than using expression alone.</p>
      <fig id="F5" position="float">
        <label>Figure 5.</label>
        <caption>
          <p>Paired sample test on matched tumor and normal in BRCA and THCA. (<bold>A</bold> and <bold>B</bold>) Volcano plots illustrate the significant interactions with −log 10(FDR) as a function of the averaged ProMISe log2 fold-change in BRCA and THCA tumors, respectively. (<bold>C</bold> and <bold>D</bold>) Three-way Venn diagram showing the overlaps among genes with differential expression (blue), genes with differential interactions (red), and putative cancer gene hubs (green) (<xref rid="B21" ref-type="bibr">21</xref>), respectively. Hypergeometric <italic>p</italic>-values are displayed near each pairwise overlap, and the common genes are displayed near the overlap.</p>
        </caption>
        <graphic xlink:href="gku182fig5"/>
      </fig>
    </sec>
    <sec id="SEC3-6">
      <title>Integrative differential analysis on breast and thyroid cancer uncovered large cancer-specific MMI network modules</title>
      <p>To visualize tumor-related changes, we generated two sets of heatmaps for BRCA and THCA using the above differential ProMISe signature and expression profiles involving the putative cancer gene hubs (<xref rid="B21" ref-type="bibr">21</xref>) (Figure <xref ref-type="fig" rid="F6">6</xref>) and OMIM genes (Supplementary Figure S7). Specifically, we performed hierarchical clustering on the selected ProMISe signature profiles. As expected, normals (blue) and tumors (red) form two distinct clusters except for only a few misclassified samples in THCA. Notably, the cancer gene hubs were derived from breast cancer cell lines (<xref rid="B21" ref-type="bibr">21</xref>), which may explain the better clustering of BRCA samples. Interestingly, we observed a slightly more consistent clustering of THCA samples when using THCA-related genes from OMIM (Supplementary Figure S8B). The overall pattern suggests a positive correlation between the miRNA expression and ProMISe, whereas the correlation between gene expression and the ProMISe signature is less straightforward. On the one hand, genes with higher (lower) expression have higher (lower) likelihood of being targeted. On the other hand, decreased (increased) MMIs may ultimately imply an increased (decreased) gene expression. Accordingly, we devised the following rule to retain only a subset of the tumor-specific interaction changes coherent with expression changes: (i) the tumor-specific differences in terms of ProMISe signature, gene and miRNA expression must be significant; (ii) the change sign between ProMISe signature and miRNA must be the same; (iii) the change sign between ProMISe signature/miRNA and gene expression must be the opposite. Some of the qualified pairs are highlighted in purple boxes in Supplementary Figure S8. In total, we obtained 1257 and 3255 qualified interactions for BRCA and THCA, corresponding to 748 (32) and 1679 (44) distinct genes (miRNAs), among which 42 (9) and 77 (15) are oncogenes (oncomirs), respectively (Supplementary Table S2). The restricted MMI forms two large network modules, harboring genes with significant up- (red) and downregulation (blue) status associated with decreased (blue edge) and increased (red edge) ProMISe signature, respectively (Figures <xref ref-type="fig" rid="F7">7</xref> and <xref ref-type="fig" rid="F8">8</xref>). For instance, the increased expression of hsa-miR-155/21/183 is coupled with increased interactions with its target genes, which exhibit decreased expression in breast tumor samples (Figure <xref ref-type="fig" rid="F7">7</xref>). Previous studies have shown the expression increase of the three miRNAs in breast cancer tissues or cell lines; however, their targetomes specific to breast cancer are not well characterized (<xref rid="B3" ref-type="bibr">3</xref>). On the other hand, BRCA-related oncomirs including let-7c and miR-145 are underexpressed in BRCA (Figure <xref ref-type="fig" rid="F7">7</xref>). Both let-7c and hsa-miR-145 are tumor suppressor genes and modulate motility, inhibit cell growth, and induce apoptosis of breast cancer cell lines (<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B27" ref-type="bibr">27</xref>). For thyroid cancer, our results remarkably show that hsa-miR-221/222 are overexpressed, consistent with the previous finding (<xref rid="B3" ref-type="bibr">3</xref>), and significantly downregulate a large cohort of genes including oncogenes ARID1A, ARNT, BCL11B, DICER1, ELK4, TCF12, TCF7L2, ARID1A, ARNT, BCL11B, DICER1, ELK4, TCF12 and TCF7L2 (Figure <xref ref-type="fig" rid="F8">8</xref>). Notably, miR-145 is also downregulated in THCA coupled with upregulation of oncogenes BCR, EML4, MAP2K4 and TPM4. Thus, the reduced activities of miR-145 are prevalent in breast, ovarian and thyroid cancers based on our results, perhaps underlining its important role in maintaining normal cell state. Together, our novel integrative approach enables discovering cancer-specific miRNAs and associating them with oncogenes at system level.</p>
      <fig id="F6" position="float">
        <label>Figure 6.</label>
        <caption>
          <p>Heatmaps using differential MMIs and expression profiles for BRCA and THCA. In each panel, three sets of heatmaps corresponding to ProMISe (from the mRNA competition model), miRNA and gene expression were generated for differential MMIs involving putative cancer gene hubs from (<xref rid="B21" ref-type="bibr">21</xref>). Blue and red column-wise color codes for normal and tumor samples, respectively. Please refer to the main text for more details.</p>
        </caption>
        <graphic xlink:href="gku182fig6"/>
      </fig>
      <fig id="F7" position="float">
        <label>Figure 7.</label>
        <caption>
          <p>Network view of the 1257 filtered MMIs for breast cancer. The filled color in the node corresponds to <italic>t</italic>-statistics from paired <italic>t</italic>-test comparing tumor with normal, where red (blue) indicates higher (lower) gene/miRNA expression in tumor. The edge color and width captures the ProMISe signature changes in <italic>t</italic>-statistics, where red (blue) indicates increased (decreased) ProMISe signature in tumor. The blown-up network modules illustrate interaction changes of the BRCA-related oncomirs hsa-miR-155/21/183/145.</p>
        </caption>
        <graphic xlink:href="gku182fig7"/>
      </fig>
      <fig id="F8" position="float">
        <label>Figure 8.</label>
        <caption>
          <p>Network view of the 3255 filtered MMIs for thyroid cancer. The blown-up images display subnetworks for hsa-miR-221/222/145. Otherwise please refer to Figure <xref ref-type="fig" rid="F7">7</xref>.</p>
        </caption>
        <graphic xlink:href="gku182fig8"/>
      </fig>
    </sec>
  </sec>
  <sec sec-type="discussion" id="SEC4">
    <title>DISCUSSION</title>
    <p>The existence of cell-type-specific expression ‘signatures’ of miRNA and gene has been previously appreciated (<xref rid="B28" ref-type="bibr">28</xref>). However, to our knowledge, there is no systematic method that identifies the MMI signature from each individual sample. In particular, most existing methods are based on negative correlation (<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B29" ref-type="bibr">29</xref>,<xref rid="B30" ref-type="bibr">30</xref>,<xref rid="B31" ref-type="bibr">31</xref>,<xref rid="B32" ref-type="bibr">32</xref>). These methods can only identify MMIs by aggregating multiple samples. In a real-world application such as cancers, however, the correlation-based methods are limited to identifying only the robust interactions due to the heterogeneity of individual expression profiles. Additionally, most existing methods are in a regression framework, by treating mRNAs as response and miRNAs as input variables, which assumes that mRNAs are independent of one another. However, mRNAs targeted by a common miRNA ‘do’ interact by competing for that miRNA (<xref rid="B9" ref-type="bibr">9</xref>). In this study, we describe a novel approach and a new class of molecular signature collectively termed as ProMISe. In essence, ProMISe signature is an <italic>N</italic> × <italic>M</italic> probability matrix for interactions between mRNA <italic>i</italic> and miRNA <italic>k</italic>. Notably, we do not normalize the probabilities so that each row or column sums to 1 because a miRNA can target multiple mRNAs with high probabilities and vice versa. Also, miRNA members in the same family (i.e. miRNAs with the same seed region) may be expressed differently. Thus, we keep them separate rather than combining them to reflect the competition within as well as between miRNA families. We explored three model formalisms, namely ‘mRNA competition’, ‘miRNA competition’ and ‘joint competition’. Although all three models compare favorably with the existing methods, our results more strongly support the mRNA competition model. Presumably, the mRNA competition has more prevalent effects on MMI because there are more potential mRNA targets per miRNA than there are miRNA regulators per mRNA.</p>
    <p>The success of our approach is based on the very fact of the miRNA targeting mechanism: each miRNA molecule can only bind to and induces degradation of one mRNA molecule at a time. This concept fits nicely with the digital read count offered by the next-generation sequencing technologies. In contrast, the same technique is not readily applicable to model transcript factor (TF)–gene interactions since the enzymatic activities of each TF can differ widely regardless of its physical abundance at mRNA or protein level. On the other hand, we also made several simplifying assumptions. First, we assume that mRNA without any seed match to a particular miRNA will have zero probabilities of being targeted by that miRNA. Recent literatures suggest a ‘seedless’ model, where miRNA can bind to regions other than 3′UTR with imperfect matches (<xref rid="B33" ref-type="bibr">33</xref>). Inclusion of seedless matches, however, will introduce a large number of false positives and thus requires a more specific model. Second, we assume the binding of miRNA will always induce the mRNA degradation, which is supported by a recent study via ribosome profiling after miRNA perturbations (<xref rid="B34" ref-type="bibr">34</xref>). However, some miRNAs may modulate gene expression primarily at the translational level (<xref rid="B35" ref-type="bibr">35</xref>,<xref rid="B36" ref-type="bibr">36</xref>). In that case, only the seed-match matrix and miRNA expression are informative to inferring MMIs. By comparing observed mRNA levels with the proteomic data (if available), we should be able to more realistically capture the mode of translational repression. Third, we assume the binding efficacy is the same between any miRNA and any mRNA. It is more realistic to use different mRNA–miRNA binding efficacy, which can be estimated from miRNA over- or underexpression data (<xref rid="B4" ref-type="bibr">4</xref>). Fourth, we do not know the grand total amount of transcripts within the cellular capacity under a specific condition. In our model, we arbitrarily assume that the total <italic>T</italic> is 30% (by default) more than the observed total. Fixing the total amount prevents ever-increasing individual total RNA levels estimated in each iteration but introduces a free parameter into the model. Since the miRNA targeting primarily occurs in the cytoplasm, it may be possible to estimate the total amount <italic>T</italic> by simultaneously measuring the RNA in both nucleus and cytoplasm using recently developed RiboMinus RNA-seq technology (<xref rid="B37" ref-type="bibr">37</xref>). Fifth, we only consider mRNAs as competitors for miRNAs in our model. Several recent studies have focused on the interplays between miRNA and long noncoding RNA (lncRNA) including pseudogene (<xref rid="B38" ref-type="bibr">38</xref>) as well as circular RNA (circRNA) (<xref rid="B39" ref-type="bibr">39</xref>), which are collectively termed as the competing endogenous RNA (ceRNA). Thus, it would be more realistic to consider the seed match and abundance of ceRNA when inferring MMI. Finally, there are many other factors that we have not considered, which nonetheless influence the outcome and our interpretation of MMI. For instance, our model only considers the total expressed seed matches at 3′UTR of mRNA for the same miRNA in the mRNA competition model and total expressed seeds of miRNA for the same mRNA in the miRNA competition model. It would be more informative to examine single nucleotide polymorphism in tumor samples, which may disrupt (introduce) existing (new) seed regions on miRNAs and/or seed matches on mRNAs. Moreover, aberrant expressions may merely be the consequence of copy number variation (CNV) at the genomic DNA level (<xref rid="B21" ref-type="bibr">21</xref>), which are not directly related to miRNA dysregulation. In tumors, some mRNAs may be regulated transiently by TF and/or miRNA, which may only be captured by single-cell RNA-seq (<xref rid="B40" ref-type="bibr">40</xref>). With more data becoming available from TCGA and elsewhere, we will examine these possibilities in future work.</p>
    <p>Comparing with other methods, the most distinct feature of ProMISe is its ability to operate on a single pair of miRNA and mRNA expression profiles measured from the same individual. This unique ability allows us to construct ProMISe signature from each individual tumor or normal sample, perform cancer diagnosis using this novel molecular signature (Figure <xref ref-type="fig" rid="F3">3</xref>), and ultimately predict tumor-specific MMIs (Figures <xref ref-type="fig" rid="F7">7</xref> and <xref ref-type="fig" rid="F8">8</xref>). For the latter, we focused our analysis on only the respective 14 and 58 matched tumor and normal samples in BRCA and THCA to mitigate heterogeneity among cancer samples. However, a significantly higher (lower) likelihood of MMI in tumor (w.r.t. normal) may merely reflect the significantly higher (lower) expression of miRNA and/or gene, which may in turn be the consequence of CNV (<xref rid="B21" ref-type="bibr">21</xref>). Although we show that genes involved in aberrant MMIs are enriched for meaningful oncogenic signature genes (Figure <xref ref-type="fig" rid="F5">5</xref>), it is important to distinguish two scenarios: (i) aberrant gene expression is caused by miRNA dysregulation; (ii) abnormal MMI reflects aberrant miRNA/gene expression. We designed a simple way to minimize the confounding effects caused by the second scenario. In particular, we focused only on the significant interactions with the same change sign as miRNA expression change but opposite change sign to the gene expression changes. Surprisingly, we were still able to obtain as many as 1257 and 3255 qualified interactions for BRCA and THCA, respectively (Supplementary Table S2). Visualizing these interactions in the network context revealed several meaningful network modules involving previously discovered and potential oncomirs and oncogenes (Figures <xref ref-type="fig" rid="F7">7 and</xref><xref ref-type="fig" rid="F8">8</xref>). From clinical perspective, the decreasing cost of genome-wide large and small RNA profiling will facilitate designing personalized medicine in small RNA therapy. Ideally, the unique ProMISe signature inferred from the paired expression profiles from an unknown sample will be compared with the categorized ProMISe signature established from existing data to identify disease-specific miRNA regulatory network modules. The knowledge link between miRNA and mRNA will enable designing drugs that control both the aberrant miRNA and gene expression synergistically.</p>
  </sec>
  <sec sec-type="supplementary-material" id="SEC5">
    <title>SUPPLEMENTARY DATA</title>
    <p>Supplementary Data are available at NAR Online, including [1–6].</p>
    <supplementary-material id="PMC_1" content-type="local-data">
      <caption>
        <title>SUPPLEMENTARY DATA</title>
      </caption>
      <media mimetype="text" mime-subtype="html" xlink:href="supp_42_9_e76__index.html"/>
      <media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_gku182_nar-03694-met-n-2013-File018.pdf"/>
      <media xlink:role="associated-file" mimetype="application" mime-subtype="vnd.ms-excel" xlink:href="supp_gku182_nar-03694-met-n-2013-File015.xlsx"/>
      <media xlink:role="associated-file" mimetype="application" mime-subtype="vnd.ms-excel" xlink:href="supp_gku182_nar-03694-met-n-2013-File017.xlsx"/>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack>
    <p>We would like to thank the anonymous reviewers for their extremely valuable suggestions.</p>
  </ack>
  <sec id="SEC6">
    <title>FUNDING</title>
    <p>Ontario Research Fund–Global Leader (Round 2); Natural Sciences and Engineering Research Council (NSERC) [327612 to Z.Z.]; NSERC Canada Graduate Scholarship and Ontario Graduate Scholarship [Y.L.]. Source of open access funding: NSERC [327612].</p>
    <p><italic>Conflict of interest statement.</italic> None declared.</p>
  </sec>
  <ref-list>
    <title>REFERENCES</title>
    <ref id="B1">
      <label>1.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bartel</surname>
            <given-names>D.P.</given-names>
          </name>
        </person-group>
        <article-title>MicroRNAs: target recognition and regulatory functions</article-title>
        <source>Cell</source>
        <year>2009</year>
        <volume>136</volume>
        <fpage>215</fpage>
        <lpage>233</lpage>
        <pub-id pub-id-type="pmid">19167326</pub-id>
      </element-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lu</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Getz</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Miska</surname>
            <given-names>E.A.</given-names>
          </name>
          <name>
            <surname>Alvarez-Saavedra</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Lamb</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Peck</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Sweet-Cordero</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Ebert</surname>
            <given-names>B.L.</given-names>
          </name>
          <name>
            <surname>Mak</surname>
            <given-names>R.H.</given-names>
          </name>
          <name>
            <surname>Ferrando</surname>
            <given-names>A.A.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>MicroRNA expression profiles classify human cancers</article-title>
        <source>Nature</source>
        <year>2005</year>
        <volume>435</volume>
        <fpage>215</fpage>
        <lpage>233</lpage>
        <pub-id pub-id-type="pmid">15889094</pub-id>
      </element-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Spizzo</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Nicoloso</surname>
            <given-names>M.S.</given-names>
          </name>
          <name>
            <surname>Croce</surname>
            <given-names>C.M.</given-names>
          </name>
          <name>
            <surname>Calin</surname>
            <given-names>G.A.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>SnapShot: microRNAs in cancer</article-title>
        <source>Cell</source>
        <year>2009</year>
        <volume>137</volume>
        <fpage>215</fpage>
        <lpage>233</lpage>
      </element-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Goldenberg</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Wong</surname>
            <given-names>K.-C.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Z.</given-names>
          </name>
        </person-group>
        <article-title>A probabilistic approach to explore human miRNA targetome by integrating miRNA-overexpression data and sequence information</article-title>
        <source>Bioinformatics</source>
        <year>2013</year>
        <fpage>215</fpage>
        <lpage>233</lpage>
        <comment>doi: 10.1093/bioinformatics/btt599</comment>
      </element-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Huang</surname>
            <given-names>J.C.</given-names>
          </name>
          <name>
            <surname>Babak</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Corson</surname>
            <given-names>T.W.</given-names>
          </name>
          <name>
            <surname>Chua</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Khan</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Gallie</surname>
            <given-names>B.L.</given-names>
          </name>
          <name>
            <surname>Hughes</surname>
            <given-names>T.R.</given-names>
          </name>
          <name>
            <surname>Blencowe</surname>
            <given-names>B.J.</given-names>
          </name>
          <name>
            <surname>Frey</surname>
            <given-names>B.J.</given-names>
          </name>
          <name>
            <surname>Morris</surname>
            <given-names>Q.D.</given-names>
          </name>
        </person-group>
        <article-title>Using expression profiling data to identify human microRNA targets</article-title>
        <source>Nature Methods</source>
        <year>2007</year>
        <volume>4</volume>
        <fpage>215</fpage>
        <lpage>233</lpage>
        <pub-id pub-id-type="pmid">17277781</pub-id>
      </element-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Qu</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Deng</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>C.</given-names>
          </name>
        </person-group>
        <article-title>A Lasso regression model for the construction of microRNA-target regulatory networks</article-title>
        <source>Bioinformatics</source>
        <year>2011</year>
        <volume>27</volume>
        <fpage>215</fpage>
        <lpage>233</lpage>
      </element-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ramaswamy</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Tamayo</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Rifkin</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Mukherjee</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Yeang</surname>
            <given-names>C.H.</given-names>
          </name>
          <name>
            <surname>Angelo</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Ladd</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Reich</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Latulippe</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Mesirov</surname>
            <given-names>J.P.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Multiclass cancer diagnosis using tumor gene expression signatures</article-title>
        <source>Proc. Natl. Acad. Sci. USA</source>
        <year>2001</year>
        <volume>98</volume>
        <fpage>215</fpage>
        <lpage>233</lpage>
      </element-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Khan</surname>
            <given-names>A.A.</given-names>
          </name>
          <name>
            <surname>Betel</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Miller</surname>
            <given-names>M.L.</given-names>
          </name>
          <name>
            <surname>Sander</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Leslie</surname>
            <given-names>C.S.</given-names>
          </name>
          <name>
            <surname>Marks</surname>
            <given-names>D.S.</given-names>
          </name>
        </person-group>
        <article-title>Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs</article-title>
        <source>Nature Biotechnology</source>
        <year>2009</year>
        <volume>27</volume>
        <fpage>215</fpage>
        <lpage>233</lpage>
      </element-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Arvey</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Larsson</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Sander</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Leslie</surname>
            <given-names>C.S.</given-names>
          </name>
          <name>
            <surname>Marks</surname>
            <given-names>D.S.</given-names>
          </name>
        </person-group>
        <article-title>Target mRNA abundance dilutes microRNA and siRNA activity</article-title>
        <source>Mol. Syst. Biol.</source>
        <year>2010</year>
        <volume>6</volume>
        <fpage>215</fpage>
        <lpage>233</lpage>
      </element-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hafner</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Landthaler</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Burger</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Khorshid</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Hausser</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Berninger</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Rothballer</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Ascano</surname>
            <given-names>M.</given-names>
            <suffix>Jr</suffix>
          </name>
          <name>
            <surname>Jungkamp</surname>
            <given-names>A.-C.</given-names>
          </name>
          <name>
            <surname>Munschauer</surname>
            <given-names>M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP</article-title>
        <source>Cell</source>
        <year>2010</year>
        <volume>141</volume>
        <fpage>215</fpage>
        <lpage>233</lpage>
      </element-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <element-citation publication-type="journal">
        <collab>Cancer Genome Atlas Research Network</collab>
        <article-title>Comprehensive genomic characterization defines human glioblastoma genes and core pathways</article-title>
        <source>Nature</source>
        <year>2008</year>
        <volume>455</volume>
        <fpage>215</fpage>
        <lpage>233</lpage>
      </element-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Subramanian</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Tamayo</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Mootha</surname>
            <given-names>V.K.</given-names>
          </name>
          <name>
            <surname>Mukherjee</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Ebert</surname>
            <given-names>B.L.</given-names>
          </name>
          <name>
            <surname>Gillette</surname>
            <given-names>M.A.</given-names>
          </name>
          <name>
            <surname>Paulovich</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Pomeroy</surname>
            <given-names>S.L.</given-names>
          </name>
          <name>
            <surname>Golub</surname>
            <given-names>T.R.</given-names>
          </name>
          <name>
            <surname>Lander</surname>
            <given-names>E.S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title>
        <source>Proc. Natl. Acad. Sci. USA</source>
        <year>2005</year>
        <volume>102</volume>
        <fpage>215</fpage>
        <lpage>233</lpage>
      </element-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Krek</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Grün</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Poy</surname>
            <given-names>M.N.</given-names>
          </name>
          <name>
            <surname>Wolf</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Rosenberg</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Epstein</surname>
            <given-names>E.J.</given-names>
          </name>
          <name>
            <surname>MacMenamin</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>da Piedade</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Gunsalus</surname>
            <given-names>K.C.</given-names>
          </name>
          <name>
            <surname>Stoffel</surname>
            <given-names>M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Combinatorial microRNA target predictions</article-title>
        <source>Nature Genetics</source>
        <year>2005</year>
        <volume>37</volume>
        <fpage>215</fpage>
        <lpage>233</lpage>
        <pub-id pub-id-type="pmid">15731754</pub-id>
      </element-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Friedman</surname>
            <given-names>R.C.</given-names>
          </name>
          <name>
            <surname>Farh</surname>
            <given-names>K.K.-H.</given-names>
          </name>
          <name>
            <surname>Burge</surname>
            <given-names>C.B.</given-names>
          </name>
          <name>
            <surname>Bartel</surname>
            <given-names>D.P.</given-names>
          </name>
        </person-group>
        <article-title>Most mammalian mRNAs are conserved targets of microRNAs</article-title>
        <source>Genome Res.</source>
        <year>2009</year>
        <volume>19</volume>
        <fpage>215</fpage>
        <lpage>233</lpage>
      </element-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Garcia</surname>
            <given-names>D.M.</given-names>
          </name>
          <name>
            <surname>Baek</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Shin</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Bell</surname>
            <given-names>G.W.</given-names>
          </name>
          <name>
            <surname>Grimson</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Bartel</surname>
            <given-names>D.P.</given-names>
          </name>
        </person-group>
        <article-title>Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs</article-title>
        <source>Nature Struct. Mol. Biol.</source>
        <year>2011</year>
        <volume>18</volume>
        <fpage>215</fpage>
        <lpage>233</lpage>
      </element-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Coronnello</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Hartmaier</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Arora</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Huleihel</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Pandit</surname>
            <given-names>K.V.</given-names>
          </name>
          <name>
            <surname>Bais</surname>
            <given-names>A.S.</given-names>
          </name>
          <name>
            <surname>Butterworth</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Kaminski</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Stormo</surname>
            <given-names>G.D.</given-names>
          </name>
          <name>
            <surname>Oesterreich</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Novel modeling of combinatorial miRNA targeting identifies SNP with potential role in bone density</article-title>
        <source>PLoS Comput. Biol.</source>
        <year>2012</year>
        <volume>8</volume>
        <fpage>e1002830</fpage>
        <pub-id pub-id-type="pmid">23284279</pub-id>
      </element-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Anders</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Mackowiak</surname>
            <given-names>S.D.</given-names>
          </name>
          <name>
            <surname>Jens</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Maaskola</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Kuntzagk</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Rajewsky</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Landthaler</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Dieterich</surname>
            <given-names>C.</given-names>
          </name>
        </person-group>
        <article-title>doRiNA: a database of RNA interactions in post-transcriptional regulation</article-title>
        <source>Nucleic Acids Res.</source>
        <year>2011</year>
        <volume>40</volume>
        <fpage>D180</fpage>
        <lpage>D186</lpage>
        <pub-id pub-id-type="pmid">22086949</pub-id>
      </element-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sing</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Sander</surname>
            <given-names>O.</given-names>
          </name>
          <name>
            <surname>Beerenwinkel</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Lengauer</surname>
            <given-names>T.</given-names>
          </name>
        </person-group>
        <article-title>ROCR: visualizing classifier performance in R</article-title>
        <source>Bioinformatics</source>
        <year>2005</year>
        <volume>21</volume>
        <fpage>3940</fpage>
        <lpage>3941</lpage>
        <pub-id pub-id-type="pmid">16096348</pub-id>
      </element-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hsu</surname>
            <given-names>S.-D.</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>F.-M.</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>W.-Y.</given-names>
          </name>
          <name>
            <surname>Liang</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>W.-C.</given-names>
          </name>
          <name>
            <surname>Chan</surname>
            <given-names>W.-L.</given-names>
          </name>
          <name>
            <surname>Tsai</surname>
            <given-names>W.-T.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>G.-Z.</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>C.-J.</given-names>
          </name>
          <name>
            <surname>Chiu</surname>
            <given-names>C.-M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>miRTarBase: a database curates experimentally validated microRNA-target interactions</article-title>
        <source>Nucleic Acids Res.</source>
        <year>2011</year>
        <volume>39</volume>
        <fpage>D163</fpage>
        <lpage>D169</lpage>
        <pub-id pub-id-type="pmid">21071411</pub-id>
      </element-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Forbes</surname>
            <given-names>S.A.</given-names>
          </name>
          <name>
            <surname>Bindal</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Bamford</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Cole</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Kok</surname>
            <given-names>C.Y.</given-names>
          </name>
          <name>
            <surname>Beare</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Jia</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Shepherd</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Leung</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Menzies</surname>
            <given-names>A.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer</article-title>
        <source>Nucleic Acids Res.</source>
        <year>2011</year>
        <volume>39</volume>
        <fpage>D945</fpage>
        <lpage>D950</lpage>
        <pub-id pub-id-type="pmid">20952405</pub-id>
      </element-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zaman</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Jaramillo</surname>
            <given-names>M.L.</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Tibiche</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Banville</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Collins</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Trifiro</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Paliouras</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Nantel</surname>
            <given-names>A.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Signaling network assessment of mutations and copy number variations predict breast cancer subtype-specific drug targets</article-title>
        <source>Cell Rep.</source>
        <year>2013</year>
        <volume>5</volume>
        <fpage>215</fpage>
        <lpage>233</lpage>
      </element-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Friedman</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Hastie</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Tibshirani</surname>
            <given-names>R.</given-names>
          </name>
        </person-group>
        <article-title>Regularization paths for generalized linear models via coordinate descent</article-title>
        <source>J. Stat. Softw.</source>
        <year>2010</year>
        <volume>33</volume>
        <fpage>215</fpage>
        <lpage>233</lpage>
      </element-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Lenferink</surname>
            <given-names>A.E.G.</given-names>
          </name>
          <name>
            <surname>Deng</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Collins</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Cui</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>Purisima</surname>
            <given-names>E.O.</given-names>
          </name>
          <name>
            <surname>O’Connor-McCourt</surname>
            <given-names>M.D.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>E.</given-names>
          </name>
        </person-group>
        <article-title>Identification of high-quality cancer prognostic markers and metastasis network modules</article-title>
        <source>Nature Commun.</source>
        <year>2010</year>
        <volume>1</volume>
        <fpage>34</fpage>
        <pub-id pub-id-type="pmid">20975711</pub-id>
      </element-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhou</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Ren</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Moore</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Mei</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>You</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Jia</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Pu</surname>
            <given-names>P.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status</article-title>
        <source>Lab. Invest.</source>
        <year>2010</year>
        <volume>90</volume>
        <fpage>215</fpage>
        <lpage>233</lpage>
      </element-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ostenfeld</surname>
            <given-names>M.S.</given-names>
          </name>
          <name>
            <surname>Bramsen</surname>
            <given-names>J.B.</given-names>
          </name>
          <name>
            <surname>Lamy</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Villadsen</surname>
            <given-names>S.B.</given-names>
          </name>
          <name>
            <surname>Fristrup</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Sørensen</surname>
            <given-names>K.D.</given-names>
          </name>
          <name>
            <surname>Ulhøi</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Borre</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Kjems</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Dyrskjøt</surname>
            <given-names>L.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors</article-title>
        <source>Oncogene</source>
        <year>2010</year>
        <volume>29</volume>
        <fpage>215</fpage>
        <lpage>233</lpage>
      </element-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Shannon</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Markiel</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Ozier</surname>
            <given-names>O.</given-names>
          </name>
          <name>
            <surname>Baliga</surname>
            <given-names>N.S.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>J.T.</given-names>
          </name>
          <name>
            <surname>Ramage</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Amin</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Schwikowski</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Ideker</surname>
            <given-names>T.</given-names>
          </name>
        </person-group>
        <article-title>Cytoscape: a software environment for integrated models of biomolecular interaction networks</article-title>
        <source>Genome Res.</source>
        <year>2003</year>
        <volume>13</volume>
        <fpage>215</fpage>
        <lpage>233</lpage>
      </element-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Götte</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Mohr</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Koo</surname>
            <given-names>C.-Y.</given-names>
          </name>
          <name>
            <surname>Stock</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Vaske</surname>
            <given-names>A.-K.</given-names>
          </name>
          <name>
            <surname>Viola</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Ibrahim</surname>
            <given-names>S.A.</given-names>
          </name>
          <name>
            <surname>Peddibhotla</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Teng</surname>
            <given-names>Y.H.-F.</given-names>
          </name>
          <name>
            <surname>Low</surname>
            <given-names>J.-Y.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness</article-title>
        <source>Oncogene</source>
        <year>2010</year>
        <volume>29</volume>
        <fpage>215</fpage>
        <lpage>233</lpage>
      </element-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sood</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Krek</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Zavolan</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Macino</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Rajewsky</surname>
            <given-names>N.</given-names>
          </name>
        </person-group>
        <article-title>Cell-type-specific signatures of microRNAs on target mRNA expression</article-title>
        <source>Proc. Natl. Acad. Sci. USA</source>
        <year>2006</year>
        <volume>103</volume>
        <fpage>215</fpage>
        <lpage>233</lpage>
      </element-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Min</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Bonner</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Z.</given-names>
          </name>
        </person-group>
        <article-title>A probabilistic framework to improve microrna target prediction by incorporating proteomics data</article-title>
        <source>J. Bioinform. Comput. Biol.</source>
        <year>2009</year>
        <volume>7</volume>
        <fpage>215</fpage>
        <lpage>233</lpage>
      </element-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Stingo</surname>
            <given-names>F.C.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>Y.A.</given-names>
          </name>
          <name>
            <surname>Vannucci</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Barrier</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Mirkes</surname>
            <given-names>P.E.</given-names>
          </name>
        </person-group>
        <article-title>A Bayesian graphical modeling approach to microRNA regulatory network inference</article-title>
        <source>Ann. Appl. Statistics</source>
        <year>2010</year>
        <volume>4</volume>
        <fpage>215</fpage>
        <lpage>233</lpage>
      </element-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Le</surname>
            <given-names>H.-S.P.</given-names>
          </name>
          <name>
            <surname>Bar-Joseph</surname>
            <given-names>Z.</given-names>
          </name>
        </person-group>
        <person-group person-group-type="editor">
          <name>
            <surname>Shawe-taylor</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Zemel</surname>
            <given-names>R.S.</given-names>
          </name>
          <name>
            <surname>Bartlett</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Pereira</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Weinberger</surname>
            <given-names>K.Q.</given-names>
          </name>
        </person-group>
        <article-title>Inferring interaction networks using the IBP applied to microRNA target prediction</article-title>
        <source>Advances in Neural Information Processing Systems 24</source>
        <year>2011</year>
        <fpage>235</fpage>
        <lpage>243</lpage>
      </element-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <name>
            <surname>Su</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Qian</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Deng</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>Predicting microRNA targets by integrating sequence and expression data in cancer</article-title>
        <source>2011 IEEE International Conference on Systems Biology (ISB), Zhuhahi, China.</source>
        <year>2011</year>
        <publisher-loc>China</publisher-loc>
        <publisher-name>ISB</publisher-name>
        <fpage>219</fpage>
        <lpage>224</lpage>
      </element-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Helwak</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Kudla</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Dudnakova</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Tollervey</surname>
            <given-names>D.</given-names>
          </name>
        </person-group>
        <article-title>Mapping the human miRNA interactome by CLASH reveals frequent noncanonical binding</article-title>
        <source>Cell</source>
        <year>2013</year>
        <volume>153</volume>
        <fpage>215</fpage>
        <lpage>233</lpage>
      </element-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Guo</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Ingolia</surname>
            <given-names>N.T.</given-names>
          </name>
          <name>
            <surname>Weissman</surname>
            <given-names>J.S.</given-names>
          </name>
          <name>
            <surname>Bartel</surname>
            <given-names>D.P.</given-names>
          </name>
        </person-group>
        <article-title>Mammalian microRNAs predominantly act to decrease target mRNA levels</article-title>
        <source>Nature</source>
        <year>2010</year>
        <volume>466</volume>
        <fpage>215</fpage>
        <lpage>233</lpage>
      </element-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Baek</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Villén</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Shin</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Camargo</surname>
            <given-names>F.D.</given-names>
          </name>
          <name>
            <surname>Gygi</surname>
            <given-names>S.P.</given-names>
          </name>
        </person-group>
        <article-title>The impact of microRNAs on protein output</article-title>
        <source>Nature</source>
        <year>2008</year>
        <volume>455</volume>
        <fpage>215</fpage>
        <lpage>233</lpage>
      </element-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Selbach</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Schwanhäusser</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Thierfelder</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Fang</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Khanin</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Rajewsky</surname>
            <given-names>N.</given-names>
          </name>
        </person-group>
        <article-title>Widespread changes in protein synthesis induced by microRNAs</article-title>
        <source>Nature</source>
        <year>2008</year>
        <volume>455</volume>
        <fpage>215</fpage>
        <lpage>233</lpage>
      </element-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sooknanan</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Pease</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Doyle</surname>
            <given-names>K.</given-names>
          </name>
        </person-group>
        <article-title>Novel methods for rRNA removal and directional, ligation-free RNA-seq library preparation</article-title>
        <source>Nature Methods|Application Notes</source>
        <year>2010</year>
        <volume>7</volume>
        <fpage>215</fpage>
        <lpage>233</lpage>
      </element-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Poliseno</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Salmena</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Carver</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Haveman</surname>
            <given-names>W.J.</given-names>
          </name>
          <name>
            <surname>Pandolfi</surname>
            <given-names>P.P.</given-names>
          </name>
        </person-group>
        <article-title>A coding-independent function of gene and pseudogene mRNAs regulates tumour biology</article-title>
        <source>Nature</source>
        <year>2010</year>
        <volume>465</volume>
        <fpage>215</fpage>
        <lpage>233</lpage>
        <pub-id pub-id-type="pmid">20463737</pub-id>
      </element-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Memczak</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Jens</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Elefsinioti</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Torti</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Krueger</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Rybak</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Maier</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Mackowiak</surname>
            <given-names>S.D.</given-names>
          </name>
          <name>
            <surname>Gregersen</surname>
            <given-names>L.H.</given-names>
          </name>
          <name>
            <surname>Munschauer</surname>
            <given-names>M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Circular RNAs are a large class of animal RNAs with regulatory potency</article-title>
        <source>Nature</source>
        <year>2014</year>
        <volume>495</volume>
        <fpage>215</fpage>
        <lpage>233</lpage>
      </element-citation>
    </ref>
    <ref id="B40">
      <label>40.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ramsköld</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Luo</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Y.-C.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Deng</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>Faridani</surname>
            <given-names>O.R.</given-names>
          </name>
          <name>
            <surname>Daniels</surname>
            <given-names>G.A.</given-names>
          </name>
          <name>
            <surname>Khrebtukova</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Loring</surname>
            <given-names>J.F.</given-names>
          </name>
          <name>
            <surname>Laurent</surname>
            <given-names>L.C.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Full-length mRNA-seq from single-cell levels of RNA and individual circulating tumor cells</article-title>
        <source>Nature Biotechnol.</source>
        <year>2012</year>
        <volume>30</volume>
        <fpage>215</fpage>
        <lpage>233</lpage>
        <pub-id pub-id-type="pmid">22398610</pub-id>
      </element-citation>
    </ref>
  </ref-list>
</back>
